Mental or Behavioral Dysfunction – Page 2 – Talk Bio

Actionable Insights Powered by AI

Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns

2 months ago talkbio0Tagged Albert, Bourla, chain disruption, Drug Industry, European (ethnic group), Manufacturing, Pfizer, Tension, TNFRSF19 gene, U.S.

Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals

2 months ago talkbio0Tagged addiction, Alcohol Use Disorder, Craving for alcohol, Glucagon-Like Peptide 1, semaglutide, Wegovy, Weight Loss Medication

semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment

Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions

3 months ago talkbio0Tagged BIOSECURE, China, DNA Sequence, Entity, Illumina, Industry, Tension, TNFRSF19 gene, unreliable

Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act

LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis

3 months ago talkbio0Tagged Autistic Disorder, biomarker test, ClearStrand-ASD, Detection, Diagnosis, Exposome, Hair Analysis, LinusBio, Negative Predictive Value of Diagnostic Test

LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine

Congressional Healthcare Reform Priorities Under Trump’s Second Term

3 months ago talkbio0Tagged Alcohol abuse, Medicaid block grants, Medicare, Prices, repeal, Translucent, Value-Based Care

ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care

RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses

3 months ago talkbio0Tagged Autistic Disorder, CHARGE Syndrome, Confirmation, Hearings, Misinformation, Response process, Robert F. Kennedy, Secretary Nomination, Senate, Vaccines, Written - Consent Mode

Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi

3 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Approved, Biogen, dosing, Eisai, Leqembi, Maintenance, Mental deterioration, monthly, United States Food and Drug Administration

Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A